Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Inclusion Criteria: Patients were eligible for inclusion if they met all of the following criteria: Informed Consent * Patients who were informed of the study procedures and medications and provided their written informed consent Demographics * Male or female * Any race * Ages 18 - 55 years * Body weight \>=20 kg and \<=150 kg * Total serum IgE concentration \>=30 and \<=700 IU/mL at Visit 0 Disease Definitions/Medications * History of at least moderate persistent allergic asthma (consistent with Global Initiative for Asthma \[GINA\] guidelines of \>=1 year in duration * On a stable asthma treatment regimen including inhaled corticosteroids for the preceding 4 weeks * An FEV1 while withholding short-acting beta-agonists for at least 6 hours and long-acting beta-agonists for at least 12 hours, of \>=75% of the predicted value at Visit 0 * Evidence of reversible airway obstruction, as defined by an increase in FEV1 of \>=12% between 20 to 30 minutes after 4 puffs (or less at the discretion of the investigator) of inhaled short-acting beta-agonist administration at Visit 0 or within the preceding year * Documented sensitivity to perennial aeroallergens, as evidenced by a positive skin test (wheal \>=5mm greater than saline control) to at least 1 of 3 perennial aeroallergens (house dust mite, cat, or dog) at Visit 0 or within the preceding year * Average PEFR variability \<=20% (calculated as \[(PM PEF - AM PEF)/(PM PEF + AM PEF)/2 x 100) during the 2-week screening period…